Consistent with these findings, PP2A is functionally inactivated in many cancers, typically through one of several different mechanisms such as somatic mutation, loss of heterozygosity and/or decreased expression of PP2A subunits, increased expression of endogenous inhibitors of PP2A and changes in phosphorylation/methylation of the C subunit. Here, PTPA is linked to cancer.